HMGB1 and colitis: Further investigation suggests that the neuroprotective properties of MSC treatments in colitis could prevent necrotic-like cell death by targeting cytokines such as high mobility group box 1 protein (HMGB1) whose levels are elevated in the faeces of colitis patients.